DNAPrint Genomics Net Income
| DNAG Stock | USD 0.00001 0.00 0.00% |
DNAPrint Genomics technical analysis allows you to utilize past data patterns in order to determine a pattern that computes the direction of the firm's future prices.
DNAPrint Genomics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.9228 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -11.1 M | -11.7 M | |
| Net Loss | -11.1 M | -11.7 M | |
| Net Loss | -11.1 M | -11.7 M | |
| Net Loss | (0.03) | (0.03) |
DNAPrint | Net Income | Build AI portfolio with DNAPrint Stock |
The Net Income trend for DNAPrint Genomics offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether DNAPrint Genomics is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest DNAPrint Genomics' Net Income Growth Pattern
Below is the plot of the Net Income of DNAPrint Genomics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in DNAPrint Genomics financial statement analysis. It represents the amount of money remaining after all of DNAPrint Genomics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is DNAPrint Genomics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DNAPrint Genomics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (12.35 M) | 10 Years Trend |
|
Net Income |
| Timeline |
DNAPrint Net Income Regression Statistics
| Arithmetic Mean | (11,967,631) | |
| Coefficient Of Variation | (9.41) | |
| Mean Deviation | 627,089 | |
| Median | (12,348,364) | |
| Standard Deviation | 1,126,426 | |
| Sample Variance | 1.3T | |
| Range | 4.6M | |
| R-Value | (0.25) | |
| Mean Square Error | 1.3T | |
| R-Squared | 0.06 | |
| Significance | 0.34 | |
| Slope | (54,879) | |
| Total Sum of Squares | 20.3T |
DNAPrint Net Income History
Other Fundumenentals of DNAPrint Genomics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
DNAPrint Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for DNAPrint Genomics is extremely important. It helps to project a fair market value of DNAPrint Stock properly, considering its historical fundamentals such as Net Income. Since DNAPrint Genomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of DNAPrint Genomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of DNAPrint Genomics' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does DNAPrint have expansion opportunities? Factors like these will boost the valuation of DNAPrint Genomics. Projected growth potential of DNAPrint fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating DNAPrint Genomics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of DNAPrint Genomics is measured differently than its book value, which is the value of DNAPrint that is recorded on the company's balance sheet. Investors also form their own opinion of DNAPrint Genomics' value that differs from its market value or its book value, called intrinsic value, which is DNAPrint Genomics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because DNAPrint Genomics' market value can be influenced by many factors that don't directly affect DNAPrint Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between DNAPrint Genomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DNAPrint Genomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DNAPrint Genomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
DNAPrint Genomics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to DNAPrint Genomics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of DNAPrint Genomics.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in DNAPrint Genomics on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding DNAPrint Genomics or generate 0.0% return on investment in DNAPrint Genomics over 90 days. DNAPrint Genomics, Inc. engages in the development and marketing of genetic testing products and services More
DNAPrint Genomics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure DNAPrint Genomics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess DNAPrint Genomics upside and downside potential and time the market with a certain degree of confidence.
DNAPrint Genomics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for DNAPrint Genomics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as DNAPrint Genomics' standard deviation. In reality, there are many statistical measures that can use DNAPrint Genomics historical prices to predict the future DNAPrint Genomics' volatility.DNAPrint Genomics Backtested Returns
We have found two technical indicators for DNAPrint Genomics, which you can use to evaluate the volatility of the firm. The firm owns a Beta (Systematic Risk) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and DNAPrint Genomics are completely uncorrelated.
Auto-correlation | 0.00 |
No correlation between past and present
DNAPrint Genomics has no correlation between past and present. Overlapping area represents the amount of predictability between DNAPrint Genomics time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of DNAPrint Genomics price movement. The serial correlation of 0.0 indicates that just 0.0% of current DNAPrint Genomics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
DNAPrint Operating Income
Operating Income |
|
Based on the recorded statements, DNAPrint Genomics reported net income of (12.35 Million). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is notably higher than that of the company.
DNAPrint Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DNAPrint Genomics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DNAPrint Genomics could also be used in its relative valuation, which is a method of valuing DNAPrint Genomics by comparing valuation metrics of similar companies.DNAPrint Genomics is currently under evaluation in net income category among its peers.
DNAPrint Fundamentals
| Return On Asset | -1.05 | ||||
| Profit Margin | (2.36) % | ||||
| Operating Margin | (7.31) % | ||||
| Current Valuation | 5.64 M | ||||
| Shares Owned By Institutions | 0.18 % | ||||
| Price To Sales | 0.20 X | ||||
| Revenue | 2.43 M | ||||
| Gross Profit | 446.37 K | ||||
| EBITDA | (5.78 M) | ||||
| Net Income | (12.35 M) | ||||
| Cash And Equivalents | 134.35 K | ||||
| Total Debt | 240 K | ||||
| Current Ratio | 0.17 X | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (5.78 M) | ||||
| Number Of Employees | 24 | ||||
| Beta | 86.78 | ||||
| Market Capitalization | 386.76 K | ||||
| Total Asset | 10.27 M | ||||
| Retained Earnings | (45.53 M) | ||||
| Working Capital | (9.35 M) | ||||
| Current Asset | 1.89 M | ||||
| Current Liabilities | 11.24 M | ||||
| Net Asset | 10.27 M |
About DNAPrint Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DNAPrint Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DNAPrint Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DNAPrint Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Can Biotechnology industry sustain growth momentum? Does DNAPrint have expansion opportunities? Factors like these will boost the valuation of DNAPrint Genomics. Projected growth potential of DNAPrint fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating DNAPrint Genomics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of DNAPrint Genomics is measured differently than its book value, which is the value of DNAPrint that is recorded on the company's balance sheet. Investors also form their own opinion of DNAPrint Genomics' value that differs from its market value or its book value, called intrinsic value, which is DNAPrint Genomics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because DNAPrint Genomics' market value can be influenced by many factors that don't directly affect DNAPrint Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between DNAPrint Genomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DNAPrint Genomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DNAPrint Genomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.